News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BIO Statement On Recent Developments In Japan's Pharmaceutical Reimbursement And Pricing System



11/23/2016 10:48:44 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

WASHINGTON--(BUSINESS WIRE)--Joseph Damond, Senior Vice President for International Affairs at the Biotechnology Innovation Organization (BIO), released the following statement in response to recent developments in Japan’s reimbursement and pricing system:

“As the world’s largest organization representing biotechnology innovators, including academic institutions, start-up enterprises, and biopharmaceutical companies of all sizes in more than 30 countries around the world, BIO regrets recent developments in Japan’s reimbursement and pricing system that make it less predictable and more risky for innovators.”

“As the world’s largest organization representing biotechnology innovators, including academic institutions, start-up enterprises, and biopharmaceutical companies of all sizes in more than 30 countries around the world, BIO regrets recent developments in Japan’s reimbursement and pricing system that make it less predictable and more risky for innovators.

“In recent years, BIO has praised initiatives in Japan that have improved its regulatory regime for new medicines as well as improved the climate for biotechnology research, development and innovation. Thus, it is disappointing to learn of recent instances of ad hoc decisions to modify prices of innovative medicines, which undermine the predictable and relatively stable rules-based system in place. BIO understands the fiscal pressures that contributed to these decisions, but believes that such issues should be treated in a holistic and deliberative manner, both to ensure that patients are not hurt by unintended consequences of decisions and that the progress Japan has made in improving incentives for biomedical research is not undermined.

“With other relevant stakeholders in Japan, BIO stands ready to work with the Government of Japan to help establish policies that promote public health and access to innovative medicines, while advancing the progress of biopharmaceutical innovation in Japan.”

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

Biotechnology Innovation Organization
George Goodno, 202-962-6660
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES